Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eran Kessous

Sports Medicine Silver Spring, MD Medical Doctor

NPI 1821033358 CMS profile 263751

11120 New Hampshire Ave, Suite 411, Silver Spring, MD 20904

Open in the dashboard

General payments

$1,443

13 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eran Kessous of Silver Spring, MD is reported in the CMS Open Payments database as having received $1,443 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23 1
2024 General $136 1
2023 General $1,043 5
2022 General $146 2
2021 General $12 1
2019 General $83 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eran Kessous
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Eran Kessous were reported at $23. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Eran Kessous Sports Medicine median Middle half National median
2019 $83 $119 $35–$362 $163
2020 $0 $77 $24–$275 $114
2021 $12 $104 $28–$340 $132
2022 $146 $94 $31–$272 $149
2023 $1,043 $91 $34–$271 $160
2024 $136 $126 $38–$294 $164
2025 $23 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pacira Pharmaceuticals Incorporated $782 2 payments
  2. Zimmer Biomet Holdings, Inc. $144 1 payment
  3. Miach Orthopaedics, Inc. $136 1 payment
  4. Acumed LLC $127 1 payment
  5. NeuroLogica Corporation, A Subsidiary of Samsung Electronics $100 1 payment
  6. Tactile Systems Technology Inc $57 1 payment
  7. Fidia Pharma USA Inc. $43 3 payments
  8. Amgen Inc. $23 1 payment
  9. Pfizer Inc. $18 1 payment
  10. DePuy Synthes Sales Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $776 12 payments
  2. Travel and Lodging $667 1 payment
Products named General payments · program years 2019–2025
  1. Iovera $667 1 payment
  2. Wrist Fusion Pins $144 1 payment
  3. ACUMED $127 1 payment
  4. Zilretta $115 1 payment
  5. Hera W10 $100 1 payment
  6. FLEXITOUCH $57 1 payment
  7. ACTITOUCH $57 1 payment
  8. ENTRE $57 1 payment
  9. HYMOVIS $43 3 payments
  10. KRYSTEXXA $23 1 payment
  11. Other $111 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$130,339

Of which drugs: $19,867

Medicare patients

158

Average age 73

Services billed

2,595

106 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Diabetes 35%
Ischemic heart disease 18%
Osteoporosis 16%
Chronic kidney disease 13%
Cancer 13%
Depression 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 26 33 $17,855
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 15 $76
Injection, ketorolac tromethamine, per 15 mg J1885 Office 20 48 $25
Injection, methylprednisolone acetate, 1 mg J1010 Office 38 52 $5
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 14 21 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record